Research Reports | Market Assessment
June 2016

Chronic Obstructive Pulmonary Disease | Access and Reimbursement | US | 2016

The U.S. therapy market for chronic obstructive pulmonary disease (COPD) is becoming increasingly crowded. As more therapies with similar clinical profiles launch and the threat of generic versions of the market leaders looms, payers have become particularly sensitive to the cost of COPD drugs. What impact does this payer pressure have on the prescribing of current therapies and the market access outlook for emerging therapies?

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports